Filter posts

Greenwood: Solving the Looming Superbug Crisis Will Require Bold Action From Congress

Writing for Morning Consult, BIO’s Jim Greenwood discusses the challenges of developing novel antibiotics and …

BIO Mourns Passing of Dr. John Holaday

On behalf of the team at BIO, we send our deepest condolences to the family …

BIO’s Jim Greenwood Talks Pricing, Policy and Science on CSPAN

BIO’s Jim Greenwood joined CSPAN’s Washington Journal for a conversation about drug pricing, the latest …

Biotech Leaders Warn: Shortsighted Policies Threaten Miracle Breakthroughs

Writing for STAT News, Paul Hastings – CEO of Nkarta Therapeutics and Vice Chair of …

How Can We Control Drug Costs While Supporting Innovation?

As the debate on drug pricing continues, our elected leaders will almost certainly adopt policies …

The DISARM Act Can Help Fix the Broken Antibiotics Market

In a recent piece for Bloomberg, reporter Robert Langreth paints a harrowing picture of the quickly …

Discussing a “Patient-Centered” Approach at BIO 2019

Placing patients at the center of everything the biotech industry stands for is a personal …

Important Perspectives on Innovation and Costs

This is an exciting time in biomedical innovation. New and highly innovative therapies are coming …

New BIO Report on State of Innovation for Alzheimer’s Disease Therapeutics

Today, BIO released a new report: The State of Innovation in Highly Prevalent Chronic Diseases …

What's Being Done to Ensure Pasta Is Here for Posterity

If you were to make a list of the world’s top 10 favorite foods, pasta …